alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2





CERTIFICATION
OF CHIEF EXECUTIVE OFFICER


AND
PRINCIPAL FINANCIAL OFFICER


PURSUANT
TO 18 U.S.C. SECTION 1350








In
connection with this Annual Report of Beauty Brands Group, Inc. (the
“Company”) on Form 10-K for the year ending December 31, 2009, as
filed with the Securities and Exchange Commission on the date hereof (the
“Report”), I, Dan Kelly, Directors and Chief Financial Officer of the
Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350,
as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002,
that:





1.
            Such
      Annual Report on Form 10-K for the year ending December 31,
      2009, fully complies with the requirements of section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





2.
            The
      information contained in such Annual Report on Form 10-K for
      the period ending December 31, 2009, fairly presents, in all
      material respects, the financial condition and results of operations
      of Equity Ventures Group, Inc.





By: /s/ Dan
Kelly


Dan
Kelly,


Director
and Chief Financial Offier





March 31,
2010
[Federal Register Volume 60, Number 98 (Monday, May 22, 1995)]
[Notices]
[Page 27118]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-12415]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF THE INTERIOR

Bureau of Land Management
[WO-350-09-1430-00]


Information Collection Submitted to the Office of Management and 
Budget for Review Under the Paperwork Reduction Act

    The proposal for the collection of information listed below has 
been submitted to the Office of Management and Budget for approval 
under provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35). 
Copies of the proposed collection of information and related forms and 
explanatory material may be obtained by contacting the Bureau's 
Clearance Officer at the phone number listed below. Comments and 
suggestions on the requirement should be made to the Bureau Clearance 
Office and to the Office of Management and Budget, Paperwork Reduction 
Project (1004-0009), Washington, D.C. 20503, telephone number 202-395-
7340.

Title: Land Use Application and Permit
OMB Approval Number: (1004-0009)
Abstract: The regulations at 43 CFR 2920 provide for non-Federal use of 
bureau administered land via lease or permit. Uses include agriculture, 
trade or manufacturing concerns and business uses such as outdoor 
recreation concession. BLM will determine the validity of uses proposed 
by private individuals and other qualified proponents from information 
provided by the proponent on the Land Use Application and Permit form
Bureau Form Number: 2920-1
Frequency: Once
Description of Respondents: Individuals, State and local government 
entities, and other qualified proponents apply for use of Bureau 
administered land via lease or permit
Estimated Completion Time: 9.60 hours
Annual Responses: 620
Annual Burden Hours: 5955
Bureau Clearance Officer: Wendy Spencer 303-236-6642

    Dated: April 15, 1995.
W. Hord Tipton,
Assistant Director, Resource Use and Protection.
[FR Doc. 95-12415 Filed 5-19-95; 8:45 am]
BILLING CODE 4310-84-M
#### Eric NEWMAN, Petitioner-Appellant, v. John ASHCROFT, et al., Respondent-Appellee.

No. 03-4259.

United States Court of Appeals, Seventh Circuit.

Submitted April 28, 2004.*

Decided April 30, 2004.

Rehearing En Banc Denied May 26, 2004.

Eric A. Newman, Terre Haute, IN, pro se.

Gerald A. Coraz, Office of the United States Attorney, Indianapolis, IN, for Respondents-Appellees.

Before RIPPLE, KANNE, and DIANE P. WOOD, Circuit Judges.

*

 After examining the briefs and the record, we have concluded that oral argument is unnecessary. Thus, the appeal is submitted on the briefs and the record. *See*Fed. R.App. P. 34(a)(2).

*419ORDER

Indiana inmate Eric Newman petitioned for a writ of habeas corpus under 28 U.S.C. § 2241, contesting his segregation in administrative detention, and requesting an order from the district court that the prison release him into the general population. The district court dismissed his suit on the ground that the “in custody” element of § 2241 was not satisfied, and we affirm.

Newman was removed from the general prison population after a disciplinary hearing officer found him guilty of fighting with another inmate and imposed sanctions, including 30 days’ disciplinary segregation. Newman served 30 days in disciplinary segregation and was then transferred to administrative detention. Newman does not contest the 30-day sanction imposed by the disciplinary hearing officer. Rather, he challenges the requirement that he remain in administrative detention for one year with clear conduct, contending that the decision to place him in administrative detention should have been preceded by notice and a hearing.

The district court correctly dismissed Newman’s habeas corpus petition because, as the court explained, Newman is not “in custody” by virtue of the administrative detention he challenges. *See*28 U.S.C. § 2241(c). Actions by prison authorities that relate only to conditions of confinement and not to the fact or duration of that confinement do not affect custody. *See Alejo v. Heller,*328 F.3d 930, 937 (7th Cir.2003); *see also Pischke v. Litscher,*178 F.3d 497, 500 (7th Cir.1999) (holding that habeas corpus relief is restricted to claims where “the prisoner is seeking to ‘get out’ of custody in a meaningful sense”). Whether Newman remains in administrative detention or is allowed to rejoin the general prison population is a decision that affects only the severity of confinement, but has no effect on its duration. *See Bunn v. Conley,*309 F.3d 1002, 1007 (7th Cir.2002); *see also Montgomery v. Anderson,*262 F.3d 641, 643 (7th Cir.2001). Newman has no liberty interest in remaining free from the imposition of administrative detention, and thus no corresponding entitlement to due process. *See Sandin v. Conner,*515 U.S. 472, 486-87, 115 S.Ct. 2293, 132 L.Ed.2d 418 (1995); *see also Wagner v. Hanks,*128 F.3d 1173, 1174-76 (7th Cir.1997). Neither does § 28 C.F.R. § 541.22, regulating prison officials’ imposition of administrative detention, create any liberty interest in freedom from administrative detention. *Crowder v. True,*74 F.3d 812, 815 (7th Cir.1996); *see also Sandin,*515 U.S. at 487.

AFFIRMED
William FLOYD, aka Jeff Floyd, et al., petitioners, v. TOWN OF HOLLYWOOD, SOUTH CAROLINA.

No. 13-434.

Supreme Court of the United States

Dec. 9, 2013.

Petition for writ of certiorari to the Supreme Court of South Carolina denied.
ADMINISTRATION

& PTV U.S. FOOD & DRUG

Food and Drug Administration
Silver Spring, MD 20993

April 4, 2023

Jeff Watson

President and Chief Executive Officer
Apotex Inc.

150 Signet Drive

Toronto, ON M9L 1T9

(416) 749-9300

Dear Mr. Watson,

The U.S. Food and Drug Administration (FDA or the Agency) is pleased to announce that Apotex
Corporation (Apotex) has been selected to receive a Drug Shortage Assistance Award for its role in
preventing or alleviating a drug shortage.

Apotex is being recognized for its efforts related to alleviating a shortage of Varenicline Tablets, 0.5 mg
and 1 mg, including temporary importation of their product and ultimately submitting and obtaining
approval of an abbreviated new drug application (ANDA 201962).

FDA established this award program to recognize companies for making a substantial contribution to
preventing or alleviating a drug shortage. FDA hopes this award serves as an incentive for other
companies to assist in addressing drug shortages, as Apotex has done.

The intent of the award program is to recognize manufacturers or companies that assist FDA in
addressing a drug shortage for their commitment to public health and quality manufacturing, a key
component of the Strategic Plan for Preventing and Mitigating Drug Shortages. More information on the
strategic plan can be found on FDA’s drug shortages web page

(http://www. fda.gov/drugs/drugsafety/drugshortages/default.htm).

FDA thanks Apotex Corp. for working to mitigate the shortage of Varenicline Tablets, 0.5 mg and 1 mg.
The enclosed press release/web statement template is provided to assist you in publicizing your award
from FDA.

Sincerely,

Jie JT -2

Douglas Throckmorton, M.D.
Deputy Center Director for Regulatory Programs,
FDA, Center for Drug Evaluation and Research


Enclosure(s):
Certificate
Optional Press Release/Web Statement Template

Ce: Andrew McNicoll, SVP, Head of Quality and Compliance, Apotex Corp.
Kiran Krishnan, SVP, Regulatory Affairs
V 

109TH CONGRESS 

1ST SESSION H. R. 1487 

For the relief of Praveen SitaRama Bobba. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 5, 2005 

Mr. HINOJOSA introduced the following bill; which was referred to the 

Committee on the Judiciary 

A BILL 

For the relief of Praveen SitaRama Bobba. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. PERMANENT RESIDENT STATUS FOR PRAVEEN 

4 SITARAMA BOBBA. 

5 (a) IN GENERAL.—Notwithstanding subsections (a) 

6 and (b) of section 201 of the Immigration and Nationality 

7 Act, Praveen SitaRama Bobba shall be eligible for 

8 issuance of an immigrant visa or for adjustment of status 

9 to that of an alien lawfully admitted for permanent resi10 dence upon filing an application for issuance of an immi11 grant visa under section 204 of such Act or for adjustment 

12 of status to lawful permanent resident. 
2 

•HR 1487 IH 

1 (b) ADJUSTMENT OF STATUS.—If Praveen SitaRama 

2 Bobba enters the United States before the filing deadline 

3 specified in subsection (c), he shall be considered to have 

4 entered and remained lawfully and shall, if otherwise eligi5 ble, be eligible for adjustment of status under section 245 

6 of the Immigration and Nationality Act as of the date of 

7 the enactment of this Act. 

8 (c) DEADLINE FOR APPLICATION AND PAYMENT OF

9 FEES.—Subsections (a) and (b) shall apply only if the ap10 plication for issuance of an immigrant visa or the applica11 tion for adjustment of status is filed with appropriate fees 

12 within 2 years after the date of the enactment of this Act. 

13 (d) REDUCTION OF IMMIGRANT VISA NUMBER.— 

14 Upon the granting of an immigrant visa or permanent res15 idence to Praveen SitaRama Bobba, the Secretary of State 

16 shall instruct the proper officer to reduce by 1, during the 

17 current or next following fiscal year, the total number of 

18 immigrant visas that are made available to natives of the 

19 country of the alien’s birth under section 203(a) of the 

20 Immigration and Nationality Act or, if applicable, the 

21 total number of immigrant visas that are made available 

22 to natives of the country of the alien’s birth under section 

23 202(e) of such Act. 

24 (e) DENIAL OF PREFERENTIAL IMMIGRATION

25 TREATMENT FOR CERTAIN RELATIVES.—The natural 
3 

•HR 1487 IH 

1 parents, brothers, and sisters of Praveen SitaRama Bobba 

2 shall not, by virtue of such relationship, be accorded any 

3 right, privilege, or status under the Immigration and Na4 tionality Act. 

Æ
I 

109TH CONGRESS 

1ST SESSION H. R. 1582 

To amend title XVIII of the Social Security Act to authorize expansion 

of Medicare coverage of medical nutrition therapy services. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 12, 2005 

Mr. UPTON (for himself, Ms. ESHOO, Mr. TERRY, Mr. WU, Mr. BECERRA, 

and Mr. BONNER) introduced the following bill; which was referred to the 

Committee on Energy and Commerce, and in addition to the Committee 

on Ways and Means, for a period to be subsequently determined by the 

Speaker, in each case for consideration of such provisions as fall within 

the jurisdiction of the committee concerned 

A BILL 

To amend title XVIII of the Social Security Act to authorize 

expansion of Medicare coverage of medical nutrition therapy services. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Medicare Medical Nu5 trition Therapy Act of 2005’’. 
2 

•HR 1582 IH 

1 SEC. 2. AUTHORIZING EXPANSION OF MEDICARE COV2 ERAGE OF MEDICAL NUTRITION THERAPY 

3 SERVICES. 

4 (a) AUTHORIZING EXPANDED ELIGIBLE POPU5 LATION.—Section 1861(s)(2)(V) of the Social Security 

6 Act (42 U.S.C. 1395x(s)(2)(V)) is amended— 

7 (1) by redesignating clauses (i) through (iii) as 

8 subclauses (I) through (III), respectively, and in9 denting each such clause an additional 2 ems; 

10 (2) by striking ‘‘in the case of a beneficiary 

11 with diabetes or a renal disease who—’’ and insert12 ing the following: 

13 ‘‘in the case of a beneficiary— 

14 ‘‘(i) with diabetes or a renal disease 

15 who—’’; 

16 (3) by adding ‘‘or’’ at the end of subclause (III) 

17 of clause (i), as so designated; and 

18 (4) by adding at the end the following new 

19 clause: 

20 ‘‘(ii) who is not described in clause (i) 

21 but who has another disease, condition, or 

22 disorder for which the Secretary has made 

23 a national coverage determination (under 

24 section 1869(f)(1)(B)) for the coverage of 

25 such services;’’. 
3 

•HR 1582 IH 

1 (b) COVERAGE OF SERVICES FURNISHED BY PHYSI2 CIANS.—Section 1861(vv)(1) of such Act (42 U.S.C. 

3 1395x(vv)(1)) is amended by inserting ‘‘, physician,’’ after 

4 ‘‘a registered dietician ’’. 

5 (c) NATIONAL COVERAGE DETERMINATION PROC6 ESS.—In making a national coverage determination de7 scribed in section 1861(s)(2)(V)(ii) of the Social Security 

8 Act, as added by subsection (a)(4), the Secretary of 

9 Health and Human Services, through the Director of the 

10 Centers for Medicare and Medicaid Services, shall— 

11 (1) consult with dietetic and nutrition profes12 sional organizations in determining appropriate pro13 tocols for coverage of medical nutrition therapy serv14 ices for individuals with different diseases, condi15 tions, and disorders; and 

16 (2) consider the degree to which medical nutri17 tion therapy interventions prevent or help prevent 

18 the onset or progression of more serious diseases, 

19 conditions, or disorders. 

20 (d) EFFECTIVE DATE.—The amendments made by 

21 this section shall apply to services furnished on or after 

22 January 1, 2006. 

Æ
[Federal Register Volume 60, Number 91 (Thursday, May 11, 1995)]
[Notices]
[Page 25204]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11642]



-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE
Department of the Air Force


Community College of the Air Force Meeting

    The Community College of the Air Force (CCAF) Board of Visitors 
will hold a meeting on Monday, June 12, 1995, at 1:00 p.m. in the AETC 
Conference Room, Building 900, Randolph AFB, Texas. The meeting is open 
to the public.
    The purpose of the meeting is to review and discuss academic 
policies and issues relative to the operation of the CCAF. Agenda items 
include a state of the college briefing, a policy council update, and 
the status of reaffirmation actions.
    For further information, contact Major Marie Morgan, (334) 953-
7937, Community College of the Air Force, Maxwell Air Force Base, 
Alabama 36112-6653.
Patsy J. Conner,
Air Force Federal Register Liaison Officer.
[FR Doc. 95-11642 Filed 5-10-95; 8:45 am]
BILLING CODE 3190-01-P
IN THE UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF INDIANA

SOUTH BEND DIVISION

CAROLYN MALONEY )

)

Plaintiff, )

)

v. ) Cause No. 3:12-cv-00842-PPS-CAN

)

NEW ENGLAND COMPOUNDING )

PHARMACY, INC. a/k/a NEW )

ENGLAND COMPOUNDING CENTER; )

AMERIDOSE, LLC; ALAUNUS )

PHARMACEUTICAL, LLC; BARRY )

CADDEN; LISA CADDEN; )

and GREGORY CONIGLIARO, )

)

Defendants. )

UNOPPOSED MOTION FOR EXTENSION OF TIME

TO RESPOND TO DEFENDANT ALAUNUS PHARMACEUTICAL, LLC'S 

MOTION TO DISMISS

Pursuant to L.R. 6.1, Plaintiff Carolyn Maloney, by counsel, hereby moves this Court for 

an extension of time to respond to Defendant Alaunus Pharmaceutical, LLC's Motion to Dismiss 

through and including April 5, 2013. Plaintiff's response is currently due March 6, 23013. 

Defendant's counsel has been consulted and has no objection to the requested extension. 

WHEREFORE, Plaintiff, by counsel prays for an Order allowing Plaintiff up to and 

including April 5, 2013 to respond to Defendant's Motion to Dismiss and for all relief just and 

proper in the premises. 

Respectfully submitted, 

/s/ Douglas A. Mulvaney __________

Douglas A. Mulvaney, # 10263-20

STUTSMAN & MULVANEY

1300 Cassopolis Street

P.O. Box 1337

Elkhart, IN 46515-1337

(574) 266-8500

case 3:12-cv-00842-PPS-CAN document 19 filed 02/18/13 page 1 of 2
CERTIFICATE OF SERVICE

This is to certify that a copy of the foregoing has been filed with the Clerk of the Court 

on February 18, 2013 using the CM/ECF system which sent notification of this filing to all 

counsel of record.

/s/ Douglas A. Mulvaney____________ 

Douglas A. Mulvaney

case 3:12-cv-00842-PPS-CAN document 19 filed 02/18/13 page 2 of 2
Alfred L. THOMPSON, petitioner, v. UNITED STATES.

No. 13-6757.

Supreme Court of the United States

Nov. 12, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the District of Columbia Circuit denied.
**EXHIBIT 32.2**

 

CERTIFICATION(pursuant to 18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002)

 

In connection with theQuarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2004of Boeing Capital Corporation (the “Company”) as filed with the U.S. Securitiesand Exchange Commission (the “Commission”) on the date hereof (the “Report”)and pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, I, Russell A. Evans, Chief Financial Officer of theCompany, certify, that:

 

(1)                                  the Report fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934,as amended; and

(2)                                  the information contained in the Report fairlypresents, in all material respects, the financial condition and results ofoperations of the Company.

 

 
| October 27, 2004 | /S/ RUSSELL A. EVANS                        |   |
|----------------------------|---------------------------------------------|--------|
|                       | Russell A. Evans                            |
|                       | Vice President and Chief  Financial Officer |

 

A signed original of this written statementrequired by Section 906 has been provided to Boeing Capital Corporation andwill be retained by Boeing Capital Corporation and furnished to the Securitiesand Exchange Commission or its staff upon request.

 

----
James Carl HIGGS, petitioner, v. Cookie CREWS, Warden.

No. 12-8911.

Supreme Court of the United States

April 29, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
<PAGE>
                                                                 Exhibit 10.31.1


NOTIFICATION TO FORMER SENIOR MANAGERS OF
ALLIANCE FOREST PRODUCTS INC - TRANSLATION

Individual letters to MM. P. Monahan, G. Cabana, J.S. Lebel, G. Auger, P. Cote,
D. Laberge, D. Laliberte, R. Provencher and Jean-Guy Gravelle.

SUBJECT : HARMONIZATION OF METHODOLOGY TO BE USED TO QUANTIFY TERMINATION
BENEFITS PAYABLE UNDER THE DEFINED BENEFITS (DB) SUPPLEMENTAL EXECUTIVE
RETIREMENT PLAN (SERP OR (TOP HAT))

Dear (surname),

As a result of pension integration for non negotiated personnel based in Canada,
for service completed since January 1, 2003, we will harmonize the methodology
to be used, if ever applicable, to quantify termination benefits payable under
the Defined Benefits (DB) Supplemental Executive Retirement Plan (SERP).

Except for Company-triggered termination without cause, if you were to leave the
employment of the Company prior to reaching age 55, termination benefits payable
under the DB SERP would be computed by using the same discount rate as the one
used to determine the commuted value of your retirement benefits payable from
the Pension Plan offered to Non-Negotiated Employees (1995) of Bowater Canadian
Forest Products Inc. (the registered plan).

In the case of Company-triggered termination without cause prior to reaching age
55, termination benefits payable from the DB SERP would be the sum of:


    A)  for service prior to January 1, 2003, the commuted value of termination
        benefits computed by using a discount rate equal to 50% of the discount
        rate used to determine the value of termination benefits payable from
        the registered plan; and
    B)  for service since January 1, 2003, the commuted value of termination
        benefits computed by using the same discount as the one used to
        determine the termination benefits payable from the registered plan.

This administrative change has no impact if you were to elect normal or early
retirement (termination of employment after age 55). Change introduced for
service since January 1, 2003 has no impact on your termination benefits prior
to reaching age 55, except if the Company were to terminate your employment
without cause. Finally, this modification does not reduce the value of your
accrued benefits as of December 31, 2002.

I remain available to answer any question you may have.



Georges Cabana,
Vice-President, Human Resources and Public Affairs, Canada

Copies : James T. Wright
         Carol Hinton
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JUN-30-1995
<PERIOD-END>                               DEC-31-1994
<CASH>                                          73,831
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                73,831
<PP&E>                                          27,550
<DEPRECIATION>                                  25,550
<TOTAL-ASSETS>                                 145,732
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       371,322
<OTHER-SE>                                   (225,590)
<TOTAL-LIABILITY-AND-EQUITY>                   145,732
<SALES>                                              0
<TOTAL-REVENUES>                                 5,141
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                22,291
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (17,150)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (17,150)
<EPS-PRIMARY>                                  (0.004)
<EPS-DILUTED>                                        0
        

</TABLE>